Stockscreener 앱 받기
16.68
2.77%
0.45
시간 외 거래:
16.69
0.01
+0.06%
Moonlake Immunotherapeutics 주식(MLTX)의 최신 뉴스
MoonLake upgraded at Rothschild & Co Redburn (MLTX:NASDAQ) - Seeking Alpha
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up After Analyst Upgrade - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Upgraded by Rothschild & Co Redburn to Buy Rating - MarketBeat
MoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn - TipRanks
Rothschild Redburn upgrades Moonlake stock on regulatory clarity - Investing.com
MoonLake stock soars as biotech fund reloads, takeover chatter ignites - MSN
MoonLake cut to sell at Goldman Sachs on risks to lead asset’s approval - MSN
MoonLake Immunotherapeutics (MLTX) price target increased by 11.25% to 22.30 - MSN
Caitong International Asset Management Co. Ltd Increases Holdings in MoonLake Immunotherapeutics $MLTX - MarketBeat
Earnings Beat: Will MoonLake Immunotherapeutics be affected by tariffs2026 EndofYear Setup & Entry Point Confirmation Signals - baoquankhu1.vn
RBC Capital Downgrades MoonLake Immunotherapeutics (MLTX) - MSN
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? - The Motley Fool
This fund acquired $28 million worth of a struggling immunotherapy stock last quarter. What important information should long-term investors consider? - Bitget
Boxer Capital Management LLC Acquires New Holdings in MoonLake Immunotherapeutics $MLTX - MarketBeat
Avoro Capital Advisors LLC Cuts Stock Position in MoonLake Immunotherapeutics $MLTX - MarketBeat
TD Cowen Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating - 富途牛牛
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
MLTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Sarepta Therapeutics (SRPT) and vTv Therapeutics (VTVT) - The Globe and Mail
Clear Street Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $70 - 富途牛牛
Clear Street raises Moonlake stock price target on IL-17 data - Investing.com Nigeria
MoonLake price target raised to $70 from $45 at Clear Street - TipRanks
Clear Street raises Moonlake stock price target on IL-17 data By Investing.com - Investing.com Australia
How Investors Are Reacting To MoonLake Immunotherapeutics (MLTX) Widening Annual Net Loss Amid Share Price Gains - simplywall.st
Trading the Move, Not the Narrative: (MLTX) Edition - Stock Traders Daily
Rhenman & Partners Asset Management AB Buys 162,000 Shares of MoonLake Immunotherapeutics $MLTX - MarketBeat
MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout - MSN
Is MoonLake Immunotherapeutics stock a smart buy before Fed meeting2026 EndofMonth & Verified Short-Term Trading Plans - Naître et grandir
TD Asset Management Inc Lowers Holdings in MoonLake Immunotherapeutics $MLTX - MarketBeat
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Positive Phase 2 Sonelokimab Results - simplywall.st
MoonLake Therapeutics Stock Sparks Retail Frenzy Ahead Of New York Summit — Traders See 'Nonstop Catalysts' Through 2026 - Stocktwits
HC Wainwright Issues Negative Outlook for MLTX Earnings - MarketBeat
What is HC Wainwright's Estimate for MLTX FY2027 Earnings? - MarketBeat
Wedbush Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $34 - 富途牛牛
MoonLake Immunotherapeutics (MLTX) Stock Analysis: Exploring a 34.94% Upside in the Biotech Sphere - DirectorsTalk Interviews
Cantor Fitzgerald reiterates Moonlake stock rating on axSpA potential - Investing.com
MoonLake Immunotherapeutics price target raised to $40 from $32 at H.C. Wainwright - TipRanks
MoonLake Immunotherapeutics (MLTX) Is Down 6.3% After Wider 2025 Loss And SLK BLA Timeline Update – Has The Bull Case Changed? - simplywall.st
Moonlake Immunotherapeutics stock price target raised to $40 by H.C. Wainwright on trial results - Investing.com India
MLTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Royal Bank Of Canada Boosts MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $13.00 - MarketBeat
Goldman Questions MoonLake Immunotherapeutics' (MLTX) Sonelokimab Approval Odds Despite Pipeline Update - Finviz
Goldman Questions MoonLake Immunotherapeutics’ (MLTX) Sonelokimab Approval Odds Despite Pipeline Update - Yahoo Finance
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
RBC Raises Price Target on MoonLake Immunotherapeutics to $13 From $12, Keeps Sector Perform, Speculative Risk - marketscreener.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and Genfit (OtherGNFTF) - The Globe and Mail
MoonLake Immunotherapeutics price target raised to $35 from $30 at Oppenheimer - TipRanks
Stifel Downgrades MoonLake Immunotherapeutics(MLTX.US) to Hold Rating, Cuts Target Price to $19 - 富途牛牛
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Mixed Share Price Performance And Premium P/B Ratio - Yahoo Finance
MoonLake’s Sonelokimab Data Sharpens Risk Reward Profile Before Phase 3 - simplywall.st
MoonLake Immunotherapeutics (MLTX) Is Down 6.7% After Mixed 2025 Results And AxSpA Data UpdateWhat's Changed - Yahoo Finance
MoonLake shares climb on encouraging AXSPA trial results - MSN
Goldman Sachs Maintains MoonLake Immunotherapeutics(MLTX.US) With Sell Rating, Raises Target Price to $11 - 富途牛牛
MoonLake Immunotherapeutics price target raised to $11 from $10 at Goldman Sachs - TipRanks
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Rating Upgraded by Zacks Research - MarketBeat
1.20%
0.06%
자본화:
|
볼륨(24시간):